Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.50 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.46 |
| ▸ | PYGM | P11217 | 3/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL3514477 | 1.00 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL20894 | 0.95 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL20895 | 0.95 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Orotic Acid SCHEMBL8148333 | 0.87 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL31685170 | 0.86 | P2RY2 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL29410228 | 0.86 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Orotidine Monophosphate SCHEMBL21891 | 0.85 | P2RY2 (0.58) | P2RY2P2RY14P2RY6P2RY4 | |
| Orotidine Monophosphate SCHEMBL12727823 | 0.85 | P2RY2 (0.58) | P2RY2P2RY14P2RY6P2RY4 | |
| Orotidine Monophosphate SCHEMBL30969958 | 0.84 | P2RY2 (0.57) | P2RY2P2RY14P2RY6P2RY4 | |
| Orotidine Monophosphate SCHEMBL20266267 | 0.84 | P2RY2 (0.57) | P2RY2P2RY14P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119432702-A | Uracil producing strain, construction method and application thereof | 新疆瑞诺生物科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-118620816-B | Uridine producing strain, construction method and application thereof | 天津科技大学 | 2024-10-29 | — | — | CN | claimed |
| CN-118620816-A | Uridine producing strain, construction method and application thereof | 天津科技大学 | 2024-09-10 | — | — | CN | claimed |
| CN-118272285-B | Uracil nucleotide production strain, directional transformation method and application thereof | 天津科技大学 | 2024-08-16 | — | — | CN | claimed |
| CN-118272285-A | Uracil nucleotide production strain, directional transformation method and application thereof | 天津科技大学 | 2024-07-02 | — | — | CN | claimed |
| CN-110564660-B | Recombinant microorganism and method for producing orotic acid | 苏州华赛生物工程技术有限公司 | 2023-03-21 | — | — | CN | claimed |
| US-20220273689-A1 | POTENTIATION OF ANTIVIRAL NUCLEOBASES AS RNA VIRUS THERAPY | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-09-01 | — | — | US | claimed |
| EP-1465616-B1 | TREATMENT OF STATIN SIDE EFFECTS USING URIDINE DERIVATIVES | MAGRAL LTD (AU) | 2010-06-30 | — | — | EP | claimed |
| US-20260146271-A1 | UDP-SUGAR BIOPRODUCTION USING MICROORGANISM HOSTS | Debut Biotechnology, Inc. (US) | 2026-05-28 | — | — | US | disclosed |
| CN-119432702-B | Uracil producing strain, construction method and application thereof | 新疆瑞诺生物科技有限公司 | 2026-04-07 | — | — | CN | disclosed |
| EP-4077359-B1 | GENETICALLY MODIFIED CLOSTRIDIUM STRAINS AND USES THEREOF | LIVINGMED BIOTECH S R L (BE) | 2026-03-18 | — | — | EP | disclosed |
| EP-3234150-B1 | FUNGAL GENOME MODIFICATION SYSTEMS AND METHODS OF USE | DANISCO US INC (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-3234151-B1 | FUNGAL GENOME MODIFICATION SYSTEMS AND METHODS OF USE | DANISCO US INC (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025111429-A1 | RECOMBINANT MICROORGANISMS WITH INCREASED ACCUMULATION AND/OR FLUX OF CYTIDINE TRIPHOSPHATE (CTP) | BP CORPORATION NORTH AMERICA INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-6130035-A | ADMINISTERING PRECURSOR OF INHIBITOR TO PATIENT, COLLECTING BODY FLUID SAMPLE, AND DETERMINING THE OROTATE OR OROTIDINE CONTENT RELATIVE TO A STANDARD OR CONTROL; INCREASED CONTENT INDICATES INCREASED DNA SYNTHESIS AND CANCER | BRUSILOW ENTERPRISE LLC (US) | 2000-10-10 | — | — | US | disclosed |
| US-6130035-A | ADMINISTERING PRECURSOR OF INHIBITOR TO PATIENT, COLLECTING BODY FLUID SAMPLE, AND DETERMINING THE OROTATE OR OROTIDINE CONTENT RELATIVE TO A STANDARD OR CONTROL; INCREASED CONTENT INDICATES INCREASED DNA SYNTHESIS AND CANCER | BRUSILOW ENTERPRISE LLC (US) | 2000-10-10 | — | — | US | disclosed |
| WO-2000042167-A1 | EUKARYOTIC CELL-BASED SYSTEM FOR IDENTIFYING GENE MODULATORS | JOHNSON & JOHNSON RESEARCH PTY. LIMITED (AU) | 2000-07-20 | — | — | WO | disclosed |
| US-5859295-A | Canavanine analogs and their use as chemotherapeutic agents | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1999-01-12 | — | — | US | disclosed |
| US-5552440-A | Use of L-canavanine as a chemotherapeutic agent for the treatment of pancreatic cancer | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0196530-A2 | Agent and process for increasing growth, for optimizing fertility and for stimulating the immune system in humans and animals | CTA Finanz AG (CH) | 1986-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273689-A1 | POTENTIATION OF ANTIVIRAL NUCLEOBASES AS RNA VIRUS THERAPY | NSUN3, NSUN2, RNMT | SLC28A1 7/4885SLC28A2 22/4885SLC29A1 17/4885 |
| US-20260146271-A1 | UDP-SUGAR BIOPRODUCTION USING MICROORGANISM HOSTS | UGGT1, GALE, UGCG | SLC28A1 964/4885SLC28A2 737/4885SLC29A1 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.